Theragnostics signs agreement with Astrazenenca

Enables development of first-in-class molecular radiotherapy based on PARP inhibitor

Offers significant potential for diagnosing and treating a broad range of cancers

LONDON, UK, 05 September 2019 – Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces a licence agreement with AstraZeneca for intellectual property (IP) that enables Theragnostics’ freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi (Poly (ADP-Ribose) Polymerase inhibitors) with an option to an exclusive licence for freedom to operate globally in the therapeutic field of certain selected radionuclide-labelled PARPi.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH